{"id":"tp-35089","type":"article-newspaper","title":"Parabilis Sets Oct. 24 ESMO Presentation for Zolucatetide Data","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/35089","datePublished":"2026-10-19T22:50:44.000Z","dateModified":"2026-10-19T22:50:44.000Z","language":"en","abstract":"The update covers data through June 22 from an ongoing Phase 1/2 study. Dose-optimization results are intended to help select a dose and schedule for a planned Phase 3 desmoid tumor trial.","section":"Business","references":[]}